GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » EV-to-FCF

InnoCare Pharma (FRA:33C) EV-to-FCF : -22.85 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, InnoCare Pharma's Enterprise Value is €321.27 Mil. InnoCare Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-14.06 Mil. Therefore, InnoCare Pharma's EV-to-FCF for today is -22.85.

The historical rank and industry rank for InnoCare Pharma's EV-to-FCF or its related term are showing as below:

FRA:33C' s EV-to-FCF Range Over the Past 10 Years
Min: -5453.08   Med: -2372.58   Max: -23.58
Current: -23.58

During the past 7 years, the highest EV-to-FCF of InnoCare Pharma was -23.58. The lowest was -5453.08. And the median was -2372.58.

FRA:33C's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.305 vs FRA:33C: -23.58

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), InnoCare Pharma's stock price is €0.58. InnoCare Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.058. Therefore, InnoCare Pharma's PE Ratio for today is At Loss.


InnoCare Pharma EV-to-FCF Historical Data

The historical data trend for InnoCare Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma EV-to-FCF Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -28.54 -3,326.81 -14.79 -4.60

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.79 - - -4.60 -

Competitive Comparison of InnoCare Pharma's EV-to-FCF

For the Biotechnology subindustry, InnoCare Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's EV-to-FCF falls into.



InnoCare Pharma EV-to-FCF Calculation

InnoCare Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=321.265/-14.06
=-22.85

InnoCare Pharma's current Enterprise Value is €321.27 Mil.
InnoCare Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCare Pharma  (FRA:33C) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

InnoCare Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.58/-0.058
=At Loss

InnoCare Pharma's share price for today is €0.58.
InnoCare Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.058.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


InnoCare Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (FRA:33C) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines